U.S. Markets closed
  • S&P Futures

    3,648.75
    +16.00 (+0.44%)
     
  • Dow Futures

    30,131.00
    +133.00 (+0.44%)
     
  • Nasdaq Futures

    12,143.75
    +67.75 (+0.56%)
     
  • Russell 2000 Futures

    1,859.20
    +7.70 (+0.42%)
     
  • Crude Oil

    44.81
    -0.10 (-0.22%)
     
  • Gold

    1,805.90
    +1.30 (+0.07%)
     
  • Silver

    23.30
    0.00 (0.00%)
     
  • EUR/USD

    1.1905
    +0.0008 (+0.0714%)
     
  • 10-Yr Bond

    0.8820
    +0.0250 (+2.92%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3364
    +0.0005 (+0.0388%)
     
  • USD/JPY

    104.4840
    +0.0040 (+0.0038%)
     
  • BTC-USD

    19,148.63
    +28.32 (+0.15%)
     
  • CMC Crypto 200

    381.39
    +11.64 (+3.15%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,678.43
    +512.84 (+1.96%)
     

Strongbridge Biopharma plc to Present at the Cowen and Company 40th Annual Healthcare Conference

DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that John H. Johnson, executive chairman, and Robert Lutz, chief financial officer, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, March 2, at 4:50 pm ET. The conference is being held at the Boston Marriott Copley Place in Boston, MA. In addition to the presentation, the Company will host a breakout session at 5:25 pm ET, immediately following the presentation.

The Company’s presentation will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.

About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.

Contacts:
Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com

Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com